Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib

Circulation

Volumn 104, Issue 19, 2001, Pages 2280-2288

  Konstam, Marvin A ^a   Weir, Matthew R ^b   Reicin, Alise ^c   Shapiro, Deborah ^c   Sperling, Rhoda S ^c   Barr, Eliav ^c   Gertz, Barry J ^c  

^a TUFTS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Anti inflammatory agents, nonsteroidal; Cardiovascular diseases; Rofecoxib; Thrombosis

Indexed keywords

CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB;

ADULT; ALZHEIMER DISEASE; ARTHRITIS; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDUCED DISEASE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; OSTEOARTHRITIS; OUTCOMES RESEARCH; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; STROKE; THROMBOSIS;

EID: 0035818601     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/hc4401.100078     Document Type: Article

References (28)

1. Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclo-oxygenase-2
2. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model
3. Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib
4. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen
5. A randomized trial comparing the effect of rofecoxib, a COX-2 specific inhibitor, to ibuprofen on the gastroduodenal mucosa of osteoarthritis patients
6. Incidence of upper gastrointestinal perforations, symptomatic ulcers, bleeding (PUBs): Rofecoxib compared to NSAIDs
7. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: A randomized, controlled, double-blind, placebo-controlled trial
8. COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects
9. Fecal blood loss after specific inhibition of cyclo-oxygenase-2: Treatment with rofecoxib compared with ibuprofen and placebo in healthy subjects
10. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
11. Cyclooxygenase inhibition and thrombogenicity
12. Collaborative overview of randomized trials of antiplatelet therapy, I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
13. Clinical pharmacology of platelet cyclooxygenase inhibition
14. Platelet-active drugs: The relationship among dose, effectiveness, and side effects
15. Evaluation of flubiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction
16. Indobufen in the prevention of thromboembolic complications in patients with heart disease: A randomized, placebo-controlled, double-blind study
17. Indobufen. An updated review of its use in the management of atherothrombosis
18. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers
19. Systemic biosythesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of selective inhibitors of COX-2 (erratum appears in Proc Natl Acad Sci U S A, 1999;96:5890)
20. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids
21. Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors: A report of four cases
22. Comparison of the frequency of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib vs. non-selective non-steroidal antiinflammatory drugs (ibuprofen, diclofenac, and nabumetone)
23. Secondary prevention of vascular disease by prolonged antiplatelet treatment
24. A rapidly converging algorithm for exact binomial confidence intervals about the relative risk in follow-up studies with stratified incidence-density data
25. Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: A comparison of nimesulide and naproxen
26. Renal effects of COX-2 selective inhibitors
27. Risk of cardiovascular events associated with selective COX-2 inhibitors
28. Aspirin for primary prevention of coronary heart disease: Safety and absolute benefit related to coronary risk derived form meta-analysis of randomized trials